Classificação em ações
#32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Negociar NuCana plc (NCNA)
Preço NCNA com a capitalização de mercado de B
Capitalização de mercado de NuCana plc(NCNA)
Valor de mercado: $9.29M
Em August 2026, NuCana plc tem uma capitalização de mercado de $9.29M. Isso faz com que NuCana plc seja a 32729th empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de NuCana plc de 2017 a 2026
NCNA comparado com o topo de 5 mais populares stocks
| Preço para NCNA |
|
Ativo B |
Capitalização de mercado de B |
Resultados |
|
|
|
|
$5.466T
|
+58,832,468.54%
|
|
|
|
|
$4.476T
|
+48,183,737.42%
|
|
|
|
|
$4.143T
|
+44,597,013.43%
|
|
|
|
|
$3.562T
|
+38,342,226.75%
|
|
|
|
|
$2.794T
|
+30,073,827.57%
|
